Orforglipron Medicine 04 June 2026 Extended indication Treatment of obesity and type 2 diabetes mellitus in adults. Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Orforglipron Domain Metabolism and Endocrinology Reason of inclusion New medicine (specialité) Main indication Diabetes Extended indication Treatment of obesity and type 2 diabetes mellitus in adults. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Eli Lilly Portfolio holder Eli Lilly Mechanism of action GLP-1 receptor agonist Route of administration Oral Therapeutical formulation Capsule Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date January 2026 Expected Registration February 2027 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options GLP1-remmers Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Orforglipron is een oraal middel dat niet op nuchtere maag hoeft te worden ingenomen. Het effect is vergelijkbaar met tirzepatide en CagriSema. Het gewichtsverlies is hoger dan Rybelsus, maar vergelijkbaar met Wegovy. Voor mensen met prikangst zijn orale GLP1-remmers een uitkomst. Duration of treatment Frequency of administration Dosage per administration References NCT05971940 (ACHIEVE-1); NCT06192108 (ACHIEVE-2); NCT06045221 (ACHIEVE-3); NCT05803421 (ACHIEVE-4); NCT06109311 (ACHIEVE-5); Expertopinie Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Declaratiedata Additional remarks In 2024 waren er meer dan 140.000 gebruikers van GLP1-remmers. Expected cost per patient per year Cost € 1,200.00 - 3,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks De prijs voor orforglipron is nog niet bekend Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks